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Effectiveness of a Peer Navigation Intervention
to Sustain Viral Suppression AmongHIV-PositiveMen
and TransgenderWomen Released From Jail
The LINK LA Randomized Clinical Trial
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Susan L. Ettner, PhD; Nina T. Harawa, PhD
IMPORTANCE Diagnosis of human immunodeficiency virus (HIV) infection, linkage and
retention in care, and adherence to antiretroviral therapy are steps in the care continuum
enabling consistent viral suppression for people living with HIV, extending longevity and
preventing further transmission. While incarcerated, people living with HIV receive
antiretroviral therapy and achieve viral suppressionmore consistently than after they are
released. No interventions have shown sustained viral suppression after jail release.
OBJECTIVE To test the effect on viral suppression in released inmates of themanualized
LINK LA (Linking Inmates to Care in Los Angeles) peer navigation intervention compared with
standard transitional case management controls.
DESIGN, SETTING, ANDPARTICIPANTS Randomized clinical trial conducted fromDecember 2012
throughOctober 2016with people livingwithHIVbeing released fromLosAngeles (LA) County
Jail. All participantswere (1) 18 years or older; (2) eithermenor transgenderwomendiagnosed
withHIV; (3) English speaking; (4) selected for the transitional casemanagement programprior
to enrollment; (5) residing in LACounty; and (6) eligible for antiretroviral therapy.
MAIN OUTCOMES ANDMEASURES Change in HIV viral suppression (<75 copies/mL) over a
12-month period.
INTERVENTIONS During the 12-session, 24-week LINK LA Peer Navigation intervention,
trained peer navigators counseled participants on goal setting and problem solving around
barriers to HIV care and adherence, starting while the participants were still in jail. After their
release, they continued counseling while they accompanied participants to 2 HIV care visits,
then facilitated communication with clinicians during visits.
RESULTS Of 356 participants randomized, 151 (42%) were black; 110 (31%) were Latino; 303
(85%) weremen; 53 (15%) were transgender women; and themean (SD) age was 39.5 (10.4)
years. At 12 months, viral suppression was achieved by 62 (49.6%) of 125 participants in the
peer navigation (intervention) arm compared with 45 (36.0%) of 125 in the transitional case
management (control) arm, for an unadjusted treatment difference of 13.6% (95% CI,
1.34%-25.9%; P = .03). In the repeatedmeasures, random effects, logistic model the adjusted
probability of viral suppression declined from 52% at baseline to 30% among controls, while
those in the peer navigation armmaintained viral suppression at 49% from baseline to 12
months, for a difference-in-difference of 22% (95% CI, 0.03-0.41; P = .02).
CONCLUSIONS AND RELEVANCE The LINK LA peer navigation intervention was successful at
preventing declines in viral suppression, typically seen after release from incarceration,
compared with standard transitional case management. Future research should examine
ways to strengthen the intervention to increase viral suppression above baseline levels.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01406626
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T he human immunodeficiency virus (HIV) care con-tinuum has emerged as the leading paradigm for con-trolling the HIV epidemic, as linkage to care, retention
in care, and viral suppression have both individual and pub-
lic health benefits.1-3 Approximately 1 in 7 HIV-positive per-
sons pass through US corrections annually,4 and HIV preva-
lence among incarcerated persons is 3 to 5 times that of the
general population.5,6 While incarcerated, people living with
HIVexperiencehighly structured environments andaccess to
health care, including antiretroviral therapy.7 They often
achieve viral suppression while incarcerated despite lacking
HIV care before entry.8-10 After release from incarceration,
many fail to link to care soon enough or long enough to sus-
tainviral suppression.9,11,12 Anobservational study found that
only 30% had filled antiretroviral prescriptions 60 days after
release fromTexasprisons.13A recent randomizedclinical trial
of a multi-component intervention among HIV-positive per-
sons leaving 2 southern state prisons showed no improve-
ment in viral suppression at 6 months after release.14 There
are no known randomized trials of any interventions shown
to sustain viral suppression over 12 months after jail release.
Weconducteda randomizedclinical trial calledLinking In-
mates toCare inLA (LosAngeles) (or “LINKLA”), apeernaviga-
tioninterventionamongHIV-positivemenandtransgenderwom-
en released from a large municipal jail system to evaluate its
effectsonviral suppression.Thetrialprotocol fromtheapplica-
tionfor funding isprovidedinSupplement1.Theconceptofpeer
navigation is rooted inpatientnavigation—thedirect assistance
providedtohelp low-income,vulnerablepatients findtheirway
through complexhealth care systems to obtain timely diagno-
sisandtreatment.15-17Whilepatientnavigatorsmayincludepro-
fessionalssuchascasemanagers,18weadoptedamodel inwhich
peernavigatorswerestrictlylaystaffmembers,whocouldbecon-
sideredpeers of theparticipants, to promote trustwith this of-
ten stigmatized population.19,20
In designing LINK LA,we hypothesized that peer naviga-
tion would improve viral suppression compared with transi-
tional case management over 12 months. We also hypoth-
esized that the intervention would be more effective among
nonusers of substances (opiates, stimulants, and binge alco-
hol) than among users.
Methods
Setting
This study was conducted from December 2012 through Oc-
tober 2016among inmatesbeing released fromLACounty Jail,
the largest jail system in theUnited States.With an estimated
62000 people living with HIV, LA County is the second larg-
est epicenter of the US epidemic after New York City.21,22 The
study was approved by the University of California, Los An-
geles Institutional Review Board, and all participants pro-
vided their written informed consent.
Study Design
LINK LA was a 2-group randomized trial: the intervention
group participated in a 12-session, 24-week peer navigation
intervention, while the control group followed the standard
transitional case management protocol. The study had a
preplanned target sample size of 356 participants. Assuming
30% attrition, and a final sample of 250 participants at 12
months (125 per arm), in simulations we had 80% power
(α = .05) to detect a minimal difference of 17% viral suppres-
sion between arms when controls had 50% viral suppres-
sion, and a 15% minimal difference when controls had 30%
viral suppression.
Eligibility and Participant Flow
Routinely, inmates were screened at intake and referred for
medical and transitional case management services if they
testedpositive forHIV.Allparticipantswere (1) 18yearsorolder;
(2) eithermen or transgenderwomendiagnosedwithHIV; (3)
English speaking; (4) selected for the transitional case man-
agementprogramprior toenrollment; (5) residing inLACounty;
and(6)eligible forantiretroviral therapy23or incarceratedwhile
undergoing antiretroviral therapy. Exclusion criteria were (1)
inability to give informed consent; (2) planned transfer to
prison; and/or (3) a stay in jail of less than 5 days. Of 465 po-
tentially eligiblepersons, 105ultimatelywerenot eligible, and
4declined.The final sample included356participants (Figure).
All 180 participants randomized to the peer navigation inter-
vention completed the first session in jail; 91% completed at
least the first 2 didactic intervention sessions (n = 163); 83%
completed at least 1 of the2 accompaniment sessions tomedi-
cal care (n = 150); and 59% completed all 12 sessions of LINK
LA (n = 106), including 2 accompaniments (Figure).
Enrollment, Randomization, and Blinding
After recruitment, staff members obtained written informed
consent andconducted thebaseline interview.Then,using se-
quentially numbered envelopes, we randomized the partici-
pants in a 1:1 ratio to the peer navigation intervention or
transitional casemanagement control groupusing computer-
generated, randomly permuted blocks of 4 and 6 to prevent
anticipationof assignment to studycondition.Toprevent con-
tamination, peer navigators interactedwith participants only
in the intervention arm and did not share interventionmate-
rials with controls. We provided basic cell phones with text
Key Points
Question What is the effect of a peer navigation intervention on
viral suppression of human immunodeficiency virus (HIV) among
people living with HIV released from jail?
Findings In the LINK LA randomized clinical trial of peer
navigation that included 356men and transgender women leaving
Los Angeles County Jail, the adjusted probability of viral
suppression among controls declined from 52% at baseline to
30%, while the LINK LA intervention groupmaintained viral
suppression at 49% from baseline to 12 months, for a significant
difference-in-difference of 22%.
Meaning The LINK LA peer navigation intervention prevented the
declines in viral suppression observed in standard care and
typically seen after release from incarceration.
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functions to all participants to arrange data collection, pro-
mote study retention, and facilitate intervention activities.
Peer Navigation Intervention
Wedeveloped themanualizedLINKLApeer navigation inter-
vention using a conceptualmodel adapted from social cogni-
tive theory, as applied to the continuum of HIV care.24,25 We
trained laypeernavigators toactas rolemodelswhocouldwalk
participants through the continuumsteps: (1) linkage or reen-
gagement, (2) retention, and (3) antiretroviral therapy adher-
ence. The peer navigation intervention addresses social-
environmental factors by promoting social support26 and
trusting relationships with peer navigators and clinicians.27
LINK LA teaches skills to overcome social stigma28 and
discrimination29and to facilitateaccess tocare30,31 throughap-
pointment scheduling, reminders, transportation assistance,
accompaniment to medical and other health care appoint-
ments, and assistance with meeting competing subsistence
needs.32 The intervention addresses personal factors by em-
phasizing the importance of retention in care and antiretro-
viral therapy adherence and advancing the knowledge and
skills necessary for engaging these activities. The interven-
tion supports behavioral factors related to HIV care and ad-
herence by promoting self-efficacy, positive health expecta-
tions, and goal-setting and problem-solving behaviors.24,25
Before theparticipantswere released from jail, peer navi-
gators delivered the intervention content during 1- to 2-hour
sessions inperson in aprivate conference room.After thepar-
ticipants were released, the navigators conducted the ses-
sions in community settings. They initiated relationshipswith
participants before they left jail, met them at the time of re-
lease, held sessions inprivate community settings, thencoun-
seled and modeled retention and adherence behaviors dur-
ing accompaniment to 2 scheduled HIV medical care
appointments up to 24 weeks after release. Navigators im-
partedthemanualizedcontent inconversational format ineach
Figure. Study Enrollment and Progress Flowchart for the LINK LA Trial
465 Referred to TCM and assessed for eligibility
356 Randomized
4 Declined participation
2 Uncomfortable discussing HIV diagnosis
2 Not interested in postrelease HIV care
assistance
105 Excluded
65 Released prior to eligibility screening
24 Impending prison sentence
6 Monolingual Spanish speaking
4 Release date after conclusion of enrollment
4 Residing outside of LAC postrelease
143 Included in 6-mo follow-up interviews (79%)
180 Intention-to-treat analysis 176 Intention-to-treat analysis
157 Included in 3-mo follow-up interviews (87%) 158 Included in 3-mo follow-up interviews (90%)
142 Included in 6-mo follow-up interviews (81%)
125 Included in 12-mo follow-up interviews (69%) 125 Included in 12-mo follow-up interviews (71%)
180 Eligible for 12-mo follow-up among intervention
participants
125 Included in 12-mo follow-up
55 Not included in 12-mo follow-up
22 Unable to locate
12 Not included before study end
9 Incarcerated in state/federal prison
6 Unwilling to continue
4 Moved from study area
2 Died
176 Eligible for 12-mo follow-up among control 
participants
125 Included in 12-mo follow-up
51 Not included in 12-mo follow-up
22 Unable to locate
13 Not released before study end
10 Incarcerated in state/federal prison
3 Unwilling to continue
1 Moved from study area
2 Died
180 Completed at least the first PN intervention session
in jail (100%)
163 Completed at least the first two didactic intervention
sessions (91%)
150 Completed at least 1 accompaniment (83%)
106 Completed all 12 sessions of intervention, including
accompaniments (59%)
176 Completed TCM intervention
HIV indicates human
immunodeficiency virus; LAC, Los
Angeles County; LINK LA, Linking
Inmates to Care in Los Angeles;
TCM, transitional case management;
PN, peer navigation.
Peer Navigation Intervention to Engage HIV-Positive Jail Inmates After Release Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine Published onlineMarch 12, 2018 E3
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of California - Los Angeles User  on 03/13/2018
session (eTable 1 in Supplement 2). During accompaniment,
navigatorspreparedparticipants forclinicianvisits, thenhelped
answer questions, took notes during the visit, and facilitated
recommendations following visits.
Peer Navigator Selection, Training, and Supervision
Peer navigators were either black or Latino (1 black woman,
1 Latina woman, 1 Latinoman, and 2 blackmen) andwere se-
lected for having experiences in common with incarcerated
people livingwithHIV (suchasprior incarceration, being apa-
tient retained inHIV care, and/or prior substance abuse recov-
ery).Peernavigatorscompletedacomprehensive, 1-weektrain-
ing regimen prior to field work, using a detailed manual of
operations.Toaddress fidelity,navigators receiveddailymoni-
toring, weekly supervision, and periodic auditing of records.
Navigatorscompletedachecklistdocumentingdeliveryofeach
session.We also held unannounced field visits to observe se-
lect intervention sessions to assure fidelity. We rated inter-
vention fidelity ona3-point scalewith 1 representinghighand
3, low fidelity. We found amean (SD) overall fidelity rating of
1.6 (0.8).
Control Intervention
The control armwas the standard of care,which is transitional
case management. All known people living with HIV in LA
County Jail received transitional case management needs as-
sessments.Transitionalcasemanagementarmparticipantsalso
receivedreferrals forpostreleasehousing,substanceabusetreat-
ment, and HIV care from case managers. Peer navigators pro-
vided these referrals to peer navigator arm participants.
Data Collection
We conducted face-to-face interviews at baseline before re-
lease, and at 3, 6, and 12months after release. At baseline, we
collected electronic medical record data on HIV viral load. At
months 3 and 12,we collectedblood samples for viral loadand
analyzed it using RealTime HIV-1 assays (Abbott Laborato-
ries). Participants were paid $25 for participation in the base-
line interview, $50 each for 3- and 6-month interviews, and
$75 for 12-month interviews plus blood samples.
OutcomeMeasures
Theprespecified primary outcomewas viral suppression, de-
fined as undetectable viral load (<75 copies/mL). We supple-
mented viral load testing with data from the LA County De-
partment of Public Health Casewatch system33 whenever
interviewed participants were not available for testing when
due. Casewatch maintains electronic record data for Ryan
White–funded clinics where most (n = 313) of the partici-
pants were seen after their release. Blinded to arm, we se-
lected viral load values closest to the scheduled data collec-
tion timepoints,within 30daysplus orminus scheduled time
points at 3 months and 12 months after release. These values
wereused for6 (2%)of the3153-month follow-upsand23 (9%)
of the 250 12-month follow-ups. The proportion of Case-
watch values used did not differ significantly by arm.
Secondary outcome measures at each follow-up (col-
lected using timeline follow-back)34 included participant-
reported informationon the following: linkage toHIV care af-
ter release (probability of HIV primary care visits); retention
in HIV care (number of HIV primary care visits, given link-
age); antiretroviral use and adherence; retention and adher-
ence knowledge (10-item scale); physical and mental health
as assessed by the 12-item short-formhealth survey (SF-12)35;
and the numbers of specialty visits,mental health visits, case
managementvisits,medication-assisted treatmentvisits, psy-
chiatrichospitalnights, emergencydepartmentvisits, anddays
of substanceuse in theprior 30days.Wevalidatedparticipant-
reportedvisitdatabyelectronicCasewatchvisit records (eTable
2 in Supplement 2).
Analysis
Weexamined theeffect of thepeernavigation interventionon
viral suppression using intention-to-treat, generalized linear
mixedmodels for longitudinallymeasureddata.Allmodels in-
cluded random intercepts for participants and used a logistic
link for viral suppression and all binary outcomes; linear link,
normal models for continuous outcomes; and zero-inflated
Poissonmodels for HIV primary care visits (retention) and all
count data outcomes.36,37 Adjusted probabilities of viral sup-
pression were estimated at baseline, months 3 and 12 for the
intervention and control arms, and differences in probabili-
tieswere estimatedbetweenarms, over timewithin arms, and
difference-in-differences over 12 months (with 95% confi-
dence intervals [CIs]). Thesemodels accommodatedatamiss-
ing at random; predictors include intervention arm, categori-
cal timeand intervention*time interactions (see the statistical
eAppendix in Supplement 2).35,36 Finally, wemodeled the ef-
fect of peernavigationon linkage to care as thebinomial prob-
ability of at least 1 visit from baseline to 3, 6, and 12 months,
by arm, and differences between arms (including 95% CIs).
To examine the heterogeneity of intervention effects,
we explored potential effect modifiers of age, race/ethnicity,
risk/gender group, education, income, insurance, substance
use, SF-12 physical and mental health scores, and CD4
count, with all main effects, 2-way and 3-way interactions
for intervention, time, and moderator predictors (including
95% CIs).
Results
Sample Characteristics
Among465screened inmates, 356 (78%)wereeligible and ran-
domized; 250 (70%) completed the 12-month interview
(Figure).Atbaseline, theparticipants reportedamean (SD) age
of39.5 (10.4)years;57%(n = 201) reportedbeingmenwhohave
sex with men; 15% (n = 53), male to female transgender sta-
tus; 42% (n = 150), an annual income of $10000 or less; 51%
(n = 180), CD4 counts lower than 500 cells/mm3; and 56%
(n = 199)no insurance (Table 1). Recentuseof substances (opi-
ates, stimulants, and binge alcohol) was prevalent (78%;
n = 277), andmeanSF-12mental healthwas a standarddevia-
tion below the US national norm.35 About half of the partici-
pants were virally suppressed (n = 184, 52%; 95% CI,
46%-57%).
Research Original Investigation Peer Navigation Intervention to Engage HIV-Positive Jail Inmates After Release
E4 JAMA Internal Medicine Published onlineMarch 12, 2018 (Reprinted) jamainternalmedicine.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of California - Los Angeles User  on 03/13/2018
Table 1. Baseline Characteristics of the Study Participants
Characteristicsa
Study Participants, No. (%)
P ValuebIntervention (n = 180) Control (n = 176) Total (n = 356)
Age, y .34
18-34 73 (41) 64 (36) 137 (39)
35-49 78 (43) 73 (42) 151 (42)
≥50 29 (16) 39 (22) 68 (19)
Race/ethnicity .58
White, non-Hispanic 47 (26) 48 (27) 95 (27)
Black, non-Hispanic 81 (45) 70 (40) 151 (42)
Hispanic 52 (29) 58 (33) 110 (31)
HIV risk group/gender .21
MSM contact 93 (52) 108 (61) 201 (57)
Male heterosexual contact 36 (20) 23 (13) 59 (17)
Male to female transgender 27 (15) 26 (15) 53 (15)
Male IV drug use 24 (13) 19 (11) 43 (12)
Educational attainment (n = 355) .15
Less than high school 75 (42) 56 (32) 131 (37)
High school or GED 47 (26) 49 (28) 96 (27)
Some college or more 58 (32) 70 (40) 128 (36)
Annual household income, $ (n = 355) .57
≤10 000 76 (42) 74 (42) 150 (42)
10 001-20 000 45 (25) 51 (29) 96 (27)
20 001-30 000 20 (11) 18 (10) 38 (11)
30 001-50 000 10 (6) 13 (7) 23 (7)
≥50 001 29 (16) 19 (11) 48 (14)
Uninsuredc 109 (61) 90 (51) 199 (56) .07
Substance use
Binge alcohol (n = 88)d 42 (23) 46 (26) 88 (25) .54
Heroin (n = 24) 15 (8) 9 (5) 24 (7) .23
Crack (n = 47) 18 (10) 29 (17) 47 (13) .07
Cocaine (n = 23) 10 (6) 13 (7) 23 (7) .48
Methamphetamine (n = 206) 104 (58) 102 (58) 206 (58) .97
Oxycodone or other opiates (n = 15) 10 (6) 5 (3) 15 (4) .20
Binge alcohold and hard drug usee 135 (75) 142 (81) 277 (78) .20
Other substances (n = 265)f 131 (73) 134 (76) 265 (74) .47
Length of stay in jail, mean (SD), wk (n = 153) 33 (30) 32 (25) 33 (27) .87
SF-12 mental health, mean (SD)g 39 (13) 38 (12) 38 (12) .31
SF-12 physical health, mean (SD)g 51 (10) 51 (10) 51 (10) .97
CD4 count, cells/mm3 (n = 355) .85
<200 21 (12) 17 (10) 38 (11)
200-349 25 (14) 29 (17) 54 (15)
350-499 44 (24) 44 (25) 88 (25)
≥500 90 (50) 85 (49) 175 (49)
Virally suppressedh 90 (50) 94 (53) 184 (52) .60
Antiretroviral therapy
Ever prescribed (n = 356) 159 (88) 159 (90) 318 (89) .54
Currently using (n = 318) 147 (92) 149 (94) 296 (93) .66
ART adherence (VAS), mean (SD)i (n = 269) 86 (24) 82 (26) 84 (25) .36
(continued)
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Effects of Peer Navigation on Viral Suppression
At 12months, 62 (49.6%) of 125 participants had achieved vi-
ral suppression in the peer navigation arm comparedwith 45
(36.0%) of 125 in the transitional case management arm, for
an unadjusted treatment difference of 13.6% (95% CI, 1.3%-
25.9%; P = .03). In the repeated measures analysis, the peer
navigationarm’sadjustedprobabilitiesofviral suppressiondid
not change from 49% at baseline to 49% atmonth 12, while it
declined from52%atbaseline to 30%at 12months in the tran-
sitional casemanagement arm (Table 2). Thus, thedifference-
in-difference of viral suppression probability over 12 months
was 22% (95% CI, 3%-41%; P = .02).
Secondary Outcomes
There was no significant difference between arms in the
probability of having at least 1 postrelease HIV primary care
visit (linkage) at 12 months, but the probability of linkage
was greater in the peer navigation arm at 6 months (differ-
ence, 12%; 95% CI, 4%-22%; P = .01; Table 3). Among those
with at least 1 visit, there was a greater increase from base-
Table 2. Effect of the LINK LA Intervention on Viral Suppressiona After Jail Release
Measurement Time
No./No. (Probabilityb)
Probability Difference (95% CI)c P ValuedIntervention Control
Baseline (n = 356) 88/180 (0.49) 91/176 (0.52) −0.04 (−0.18 to 0.10) .60
3 Months (n = 315) 82/157 (0.53) 63/158 (0.37) 0.16 (0.01 to 0.31) .03
Change at 3 months (95% CI)c,e 0.04 (−0.08 to 0.17) −0.16 (−0.28 to −0.03)f 0.20 (0.02 to 0.38) .02
12 Months (n = 250) 62/125 (0.49) 45/125 (0.30) 0.18 (0.02 to 0.40) .03
Change at 12 months (95% CI)c,e 0.003 (−0.130 to 0.140) −0.22 (−0.35 to −0.09)g 0.22 (0.03 to 0.41) .02
Abbreviations: GLMM, generalized linear mixedmodel; LINK LA, Linking
Inmates to Care in Los Angeles.
a Viral suppression is measured as the probability of having an undetectable
viral load (<75 copies/mL) at each follow-up session by study arm using a
repeatedmeasures, random-intercept, logistic model (a GLMM) with
predictors of study arm, categorical time, and intervention × time interaction.
Themodel accommodates data missing at random, and loss to follow-up was
not different between study arms.
b Probability is not necessarily equal to the numerator divided by the
denominator because the probabilities are estimated from the
random-intercept, logistic GLMMs.
c Intervention arm valueminus control arm value; probability differences are
not always precise totals owing to rounding.
dP value for test between intervention and control arm values at each follow-up
period and difference-in-difference tested for change from baseline by study
arm, based on the single random-intercept, logistic GLMM.
e Follow-up interview valueminus baseline value.
f P < .05 for change from baseline.
g P < .01 for change from baseline.
Table 1. Baseline Characteristics of the Study Participants (continued)
Characteristicsa
Study Participants, No. (%)
P ValuebIntervention (n = 180) Control (n = 176) Total (n = 356)
Preincarceration utilization measuresj
HIV primary care visits (n = 350) 27 (15) 24 (14) 51 (15) .75
Specialty care visits (n = 351) 22 (12) 26 (15) 48 (14) .47
Mental health visits (n = 352) 58 (33) 54 (31) 112 (32) .76
Case manager visits (n = 350) 71 (40) 63 (37) 134 (38) .53
MAT visits (n = 352)k 44 (25) 46 (26) 90 (26) .71
Psychiatric hospital nights (n = 351) 47 (26) 51 (29) 98 (28) .52
ED visits (n = 351) 87 (49) 85 (49) 172 (49) .96
Abbreviations: ART, antiretroviral therapy; ED, emergency department;
GED, general equivalency diploma; HIV, human immunodeficiency virus; IV,
intravenous; MAT, medication assisted treatment; MSM, menwho have sex
with men; SF-12, 12-item short-form health survey35; VAS, visual analogue scale.
a Data are reported as the total number of participants with nonmissing data on
each item, generally n = 356; however, in categories where data were missing,
the total number of participants for whom data were available is reported
after each category name.
bEquality of the difference in proportions between study arms at baseline
tested using the χ2 test.
c Insured category (reference group) includes participants with private
insurance (5%, n = 19), Medicaid/Medi-Cal (22%, n = 77), or other public
insurance (17%, n = 61).
d Binge alcohol is defined as 5 or more alcoholic drinks at a time.
e Hard drugs include heroin, crack cocaine, powder cocaine,
methamphetamines, and/or oxycodone or other opiates.
f Other substances includemarijuana, barbiturates, valium, or other
sedative-hypnotics, ecstasy, LSD or other hallucinogens, and any alcohol.
g SF-12 Mental Component and Physical Component Scores (T-scores, normed
to US general population: mean (SD) score, 50 (10).35
hDefined as undetectable viral load, based on the laboratory limit of detection
75 copies/mL.
i ART adherence is defined as themean percentage of ART doses taken, among
those prescribed and using ART, measured using a VAS.
j Included are participants who reported at least 1 visit of the specified type in
the 12 months prior to incarceration, measured by timeline follow-back.
k MAT visits include those for prescriptionmedications such as methadone or
buprenorphine to treat addiction to drugs or alcohol.
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line in the number of visits per year (retention) since release
in the peer navigation arm than in the control arm over 12
months (difference, 0.71; 95% CI, 0.01-1.40; P = .047)
(Table 3). While the intervention improved retention and
adherence knowledge at 12 months, more than 90% of par-
ticipants (n = 296 of 321) reported currently using antiretro-
viral therapy in both arms and all follow-up periods
(Table 4). Similarly, mean self-reported adherence exceeded
80% in both arms and all follow-up periods. Peer navigation
arm participants reported a greater increase in number per
year of mental health visits at 3 months (21.6; 95% CI, 12.2-
31.0; P < .001) and 6 months (13.6; 95% CI, 7.0-20.2;
P < .001), case management visits at 3 months (10.0; 95% CI,
4.3-15.8; P < .001) and 6 months (14.3; 95% CI, 9.9-18.7;
P < .001), medication-assisted treatment visits at 6 months
(2.4; 95% CI, 0.02-4.8; P = .048), psychiatric hospital nights
at 3 months (125.3; 95% CI, 36.4-214.2; P = .01); and they had
fewer emergency department visits at 3 months (−1.2; 95%
CI, −2.0 to −0.3; P = .01) and 6 months (−0.5; 95% CI, −0.9 to
−0.1; P = .005). Control arm participants had a greater
increase in the number of specialty visits at 3 months and
medication-assisted treatment visits at 12 months. There
was no effect on reported substance use, although use
declined substantially in both arms, particularly at 3 months,
and remained lower than baseline at 12 months (eTable 3 in
Supplement 2).
Substance Use andOther Potential Moderators
Wehypothesized that the interventioneffectwouldbegreater
amongnon–substanceusers than among substanceusers, but
the evidence did not support this. However, the intervention
wasmosteffectiveat 12monthsamong thehomeless (P = .004
for the interaction) and those whowere virally suppressed at
baseline (P < .001 for the interaction). See eTable 4 in
Supplement 2 for supporting data.
Discussion
In this study of people living with HIV released from a large
metropolitan jail, theLINKLApeernavigation interventionbet-
ter maintained viral suppression over 12 months than transi-
tional case management, for a 22% adjusted difference-
in-difference. No prior interventions to our knowledge have
shown a sustained level of viral suppression after jail release
amongpeople livingwithHIVreentering thecommunity.Aran-
domizedclinical trial14 comparingamotivational interviewing/
care-coordination interventionwithstandardcare foundabout
60% viral suppression in both arms at 6months after release
from2southernUSprisonsand temporaldeclines inbotharms
from over 85% before release. Two recently published trials
of somewhat similar interventions (patient navigation,18 peer
mentors38) among people living with HIV after hospitaliza-
tion did not find that viral suppression was significantly bet-
ter in the intervention groups than among controls at 12
months. However, attending more patient navigation ses-
sions was associated with improved viral suppression at 6
months in the trial of patient navigation plus financial
incentives.18,39Although the level of viral suppressiondidnot
increase from baseline in LINK LA, the peer navigation
Table 3. Effect of the LINK LA Intervention on Linkage to and Retention in HIV Primary Care After Jail Releasea
Measurement Time
Intervention (95% CI)
(n = 180)
Control (95% CI)
(n = 176)
Difference
(95% CI)b,c P Valued
Linkage to HIV Caree
0-3 Months (n = 312) 0.64 (0.57 to 0.72) 0.63 (0.56 to 0.71) 0.01 (−0.09 to 0.12) .81
0-6 Months (n = 260) 0.89 (0.84 to 0.95) 0.77 (0.69 to 0.84) 0.12 (0.04 to 0.22) .01
0-12 Months (n = 220) 0.92 (0.87 to 0.97) 0.88 (0.82 to 0.94) 0.04 (−0.04 to 0.12) .32
Retention in HIV Caref
Baseline (n = 350) 1.64 (1.29 to 2.00) 2.26 (1.74 to 2.77) −0.61 (−1.24 to 0.01)g .054
3 Months (n = 312) 3.08 (2.56 to 3.61) 3.04 (2.52 to 3.55) 0.04 (−0.69 to 0.77) .90
Change at 3 months (n = 307)a,c 1.44 (0.89 to 1.98)h 0.78 (0.18 to 1.38)g 0.66 (−0.15 to 1.47) .11
6 Months (n = 261) 2.15 (1.79 to 2.50) 2.15 (1.75 to 2.55) −0.001 (−0.54 to 0.53) >.99
Change at 6 months (n = 256)a,c 0.50 (0.10 to 0.90)g −0.11 (−0.66 to 0.44) 0.61 (−0.07 to 1.30) .08
12 Months (n = 235) 2.25 (1.87 to 2.64) 2.16 (1.79 to 2.53) 0.09 (−0.44 to 0.62) .73
Change at 12 months (n = 232)a,c 0.61 (0.17 to 1.06)g −0.10 (−0.63 to 0.44) 0.71 (0.01 to 1.40)g .047
Abbreviations: GLMM, generalized linear mixedmodel; HIV, human
immunodeficiency virus; LINK LA, Linking Inmates to Care in Los Angeles;
ZIP, zero-inflated Poisson.
a Follow-up interview valueminus baseline value.
b Intervention arm estimate minus control arm estimate.
c Difference and change values are not always precise totals owing to rounding.
dP value for test between intervention and control arm values at each
measurement time and difference-in-difference tested for change from
baseline by study arm, based on a single regressionmodel.
e Probability of havingHIV primary care visits frombaseline (0months) to each
measurement time at 3, 6, and 12months after release from incarceration by arm,
and difference (with 95%CIs) estimated using unadjusted binomialmodel.
f Estimated number of HIV primary care visits over the preceding 3months,
given linkage to care (at least 1 visit), using a repeatedmeasures,
random-intercept, ZIP model (a GLMM) with predictors of intervention arm,
categorical time, and intervention × time interaction. Themodel
accommodates data missing at random, and loss to follow-up was not
different between study arms. ZIP models had 2 uncorrelated random effects,
one for the zero-inflation component and the other for the Poisson
component. All values are estimated per-12-month rate, given at least 1 visit
(or hospital night) in the previous 12 months.
g P < .05 for change from baseline.
hP < .001 for change from baseline
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Table 4. Effect of the LINK LA Intervention on Secondary Outcomes After Jail Releasea
Measurement Time
No./Total No.; Probability (95% CI)
Difference (95% CI)b P ValuecIntervention Control
Current ART Used
Baseline (n = 321) 147/161; 0.98 (0.96 to 1.00) 149/160; 0.99 (0.97 to 1.00) −0.01 (−0.03 to 0.01) .49
3 Months (n = 315) 128/157; 0.94 (0.90 to 0.99) 130/158; 0.95 (0.92 to 0.99) −0.01 (−0.06 to 0.04) .69
Change at 3 monthsb,e −0.040 (−0.070 to 0.001) −0.0300 (−0.0700 to −0.0002)f −0.003 (−0.050 to 0.050) .90
6 Months (n = 285) 116/143; 0.94 (0.89 to 0.98) 111/142; 0.92 (0.86 to 0.98) 0.02 (−0.05 to 0.08) .65
Change at 6 monthsb,e −0.0400 (−0.0800 to 0.0001)f −0.07 (−0.12 to −0.01) 0.02 (−0.04 to 0.09) .49
12 Months (n = 250) 104/125; 0.95 (0.91 to 0.99) 107/125; 0.96 (0.93 to 0.996) −0.01 (−0.06 to 0.03) .60
Change at 12 monthsb,e −0.03 (−0.07 to 0.01) −0.02 (−0.05 to 0.01) −0.01 (−0.05 to 0.04) .82
Adherence to ARTg,h
Baseline (n = 354) (98) 85.7 (80.8 to 90.7) (109) 81.6 (76.9 to 86.3) 4.1 (−2.7 to 10.9) .54
3 Months (n = 315) (116) 85.1 (80.7 to 89.5) (121) 82.6 (78.3 to 86.9) 2.5 (−3.6 to 8.7) .40
Change at 3 monthsb,e −0.6 (−7.3 to 6.0) 0.95 (−5.5 to 7.4) −1.6 (−10.8 to 7.7) .38
6 Months (n = 285) (110) 88.4 (84.5 to 92.3) (101) 86.1 (82.0 to 90.1) 2.4 (−3.3 to 8.0) .20
Change at 6 monthsb,e 2.7 (−3.4 to 8.8) 4.5 (−1.5 to 1.4) −1.8 (−10.3 to 6.7) .14
12 Months (n = 250) (96) 86.7 (82.4 to 91.1) (101) 85.4 (81.2 to 89.7) 1.3 (−4.8 to 7.4) .50
Change at 12 monthsb,e 1.0 (−5.4 to 7.4) 3.8 (−2.3 to 9.9) −2.8 (−11.6 to 6.1) .20
Retention and Adherence Knowledgeh,i
Baseline (n = 354) (176) 8.9 (8.7 to 9.0) (176) 9.0 (8.8 to 9.1) −0.1 (−0.3 to 0.1) .35
3 Months (n = 315) (158) 8.9 (8.8 to 9.1) (158) 9.0 (8.9 to 9.2) −0.1 (−0.3 to 0.1) .42
Change at 3 monthsb,e 0.06 (−0.10 to 0.30) 0.05 (−0.10 to 0.30) 0.01 (−0.30 to 0.30) .95
6 Months (n = 285) (142) 9.0 (8.8 to 9.1) (142) 9.05 (8.90 to 9.20) −0.1 (−0.3 to 0.1) .40
Change at 6 monthsb,e 0.08 (−0.1 to 0.3) 0.07 (−0.10 to 0.30) 0.01 (−0.30 to 0.30) .95
12 Months (n = 250) (125) 9.2 (9.0 to 9.3) (125) 9.0 (8.8 to 9.1) 0.20 (−0.06 to 0.40) .14
Change at 12 monthsb,e 0.30 (0.08 to 0.5)j −0.002 (−0.200 to 0.200) 0.30 (0.01 to 0.60)f .04
SF-12 Physical Healthh,k
Baseline (n = 352) (180) 51.4 (49.9 to 53.0) (172) 51.4 (49.9 to 53.0) 0.02 (−2.1 to 2.2) .99
3 Months (n = 309) (154) 48.5 (46.8 to 50.2) (155) 47.9 (46.2 to 49.6) 0.5 (−1.9 to 2.9) .67
Change at 3 monthsb,e −3.0 (−4.6 to −1.4)l −3.5 (−5.1 to −1.9)l 0.5 (−1.8 to 2.8) .66
6 Months (n = 274) (138) 48.5 (46.7 to 50.3) (136) 48.2 (46.4 to 49.9) 0.4 (−2.2 to 2.9) .77
Change at 6 monthsb,e −2.9 (−4.8 to −1.0)j −3.3 (−5.2 to −1.4)l 0.4 (−2.3 to 3.0) .80
12 Months (n = 248) (124) 48.6 (46.8 to 50.5) (124) 46.5 (44.7 to 48.3) 2.1 (−0.5 to 4.7) .11
Change at 12 monthsb,e −2.8 (−4.7 to −0.9)j −4.9 (−6.9 to −3.01)l 2.1 (−0.6 to 4.8) .13
SF-12Mental Healthh,k
Baseline (n = 352) (180) 38.9 (37.1 to 40.7) (172) 37.6 (35.7 to 39.4) 1.3 (−1.3 to 3.9) .32
3 Months (n = 309) (154) 41.0 (39.1 to 42.9) (155) 39.9 (38.0 to 41.8) 1.1 (−1.6 to 3.8) .42
Change at 3 monthsb,e 2.10 (0.08 to 4.20)f 2.3 (0.3 to 4.4)f −0.2 (−3.1 to 2.7) .88
6 Months (n = 274) (138) 40.4 (38.4 to 42.4) (136) 40.7 (38.7 to 42.7) −0.3 (−3.1 to 2.5) .84
Change at 6 monthsb,e 1.5 (−0.5 to 3.5) 3.1 (1.1 to 5.1)j −1.6 (−4.4 to 1.2) .27
12 Months (n = 248) (124) 40.1 (38.0 to 42.2) (120) 41.3 (39.2 to 43.4) −1.2 (−4.1 to 1.8) .44
Change at 12 monthsb,e 1.3 (−0.9 to 3.4) 3.7 (1.6 to 5.9)l −2.5 (−5.5 to 0.6) .11
Specialty Care Visitsm
Baseline (n = 351) 22/178; 3.8 (2.8 to 4.9) 26/173; 5.3 (3.3 to 7.2) −1.4 (−3.6 to 0.7) .19
3 Months (n = 311) 34/156; 3.6 (2.5 to 4.7) 31/155; 6.5 (4.0 to 8.9) −2.8 (−5.5 to −0.2) .04
Change at 3 monthsb −0.2 (−1.3 to 0.9) 1.2 (−1.2 to 3.6) −1.4 (−4.0 to 1.2) .30
6 Months (n = 262) 39/133; 3.6 (2.6 to 4.5) 36/129; 4.4 (3.1 to 5.7) −0.8 (−2.4 to 0.7) .30
Change at 6 monthsb −0.3 (−1.1 to 0.6) −0.9 (−2.7 to 1.0) 0.6 (−1.4 to 2.6) .55
12 Months (n = 235) 38/117; 6.9 (4.6 to 9.2) 35/118; 7.0 (4.5 to 9.5) −0.1 (−3.4 to 3.3) .97
Change at 12 monthsb 3.1 (1.3 to 5.0)l 1.7 (−0.7 to 4.2) 1.4 (−1.7 to 4.5) .38
Mental Health Visitsn
Baseline (n = 352) 58/178; 10.1 (6.5 to 13.6) 54/174; 10.2 (6.4 to 14.1) −0.1 (−4.8 to 4.5) .95
3 Months (n = 310) 48/156; 31.9 (19.6 to 44.2) 43/154; 10.4 (6.1 to 14.7) 21.5 (9.2 to 33.8) <.001
Change at 3 monthsb 21.8 (12.7 to 30.9)l 0.2 (−2.3 to 2.7) 21.6 (12.2 to 31.0)l <.001
6 Months (n = 261) 53/133; 24.6 (15.2 to 34.0) 44/128; 11.1 (6.6 to 15.6) 13.5 (3.8 to 23.1) .01
Change at 6 monthsb 14.5 (8.3 to 20.8)l 0.9 (−1.4 to 3.2) 13.6 (7.0 to 20.2)l <.001
12 Months (n = 235) 40/117; 14.7 (9.0 to 20.4) 40/118; 20.2 (11.8 to 28.7) −5.5 (−14.9 to 3.8) .25
Change at 12 monthsb 4.6 (1.6 to 7.6)j 10.0 (4.7 to 15.3)l −5.4 (−11.4 to 0.6) .08
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intervention was successful at preventing the declines
in viral suppression usually observed after release from
incarceration.9,12,13,40,41
The baseline probability of 49% viral suppression sus-
tainedbyLINKLAparticipants in the interventionarm is com-
parable to thatobserved inother studiesof incarceratedpeople
living with HIV,39,42 while suppression among controls de-
clined to 30% at 12 months. Achievement of viral suppres-
sion is important because it promotes immune reconstitu-
tionandvirtuallyeliminatesHIV transmission.43Also, the49%
Table 4. Effect of the LINK LA Intervention on Secondary Outcomes After Jail Releasea (continued)
Measurement Time
No./Total No.; Probability (95% CI)
Difference (95% CI)b P ValuecIntervention Control
Case Manager Visitso
Baseline (n = 351) 71/178; 9.6 (6.8 to 12.4) 63/172; 10.9 (7.9 to 14.0) −1.3 (−5.0 to 2.3) .47
3 Months (n = 311) 100/156; 25.5 (17.7 to 33.3) 78/155; 16.9 (12.1 to 21.6) 8.7 (0.4 to 17.0) .04
Change at 3 monthsb 16.0 (10.6 to 21.3)l 5.9 (3.3 to 8.6)l 10.0 (4.3 to 15.8) <.001
6 Months (n = 262) 66/133; 19.7 (13.6 to 25.8) 53/128; 6.7 (4.9 to 8.5) 13.0 (6.9 to 19.0) <.001
Change at 6 monthsb 10.1 (6.3 to 14.0)l −4.2 (−6.1 to −2.3)l 14.3 (9.9 to 18.7) <.001
12 Months (n = 235) 54/117; 11.3 (7.8 to 14.7) 57/118; 10.7 (7.6 to 13.9) 0.5 (−3.7 to 4.7) .81
Change at 12 monthsb 1.7 (−0.1 to 3.5) −0.2 (−2.1 to 1.7) 1.9 (−0.8 to 4.5) .17
Medication Assisted Treatment Visitsp
Baseline (n = 351) 4/178; 6.9 (4.8 to 9.0) 5/173; 4.5 (3.3 to 5.8) 2.3 (−0.1 to 4.7) .06
3 Months (n = 311) 10/156; 7.5 (4.7 to 10.2) 3/155; 4.7 (3.1 to 6.4) 2.7 (−0.5 to 5.9) .09
Change at 3 monthsb 0.6 (−1.5 to 2.7) 0.2 (−1.2 to 1.6) 0.4 (−2.1 to 2.9) .76
6 Months (n = 262) 11/133; 8.8 (5.4 to 13.1) 4/129; 4.0 (2.8 to 5.2) 4.7 (1.6 to 7.9) .003
Change at 6 monthsb 1.6 (−0.1 to 3.3) −0.6 (−1.6 to 0.5) 2.40 (0.02 to 4.80)f .05
12 Months (n = 235) 3/117; 5.5 (3.5 to 7.5) 9/118; 7.3 (4.7 to 9.9) −1.8 (−5.1 to 1.5) .28
Change at 12 monthsb −1.4 (−3.2 to 0.4) 2.8 (0.8 to 4.7)j −4.1 (−6.8 to −1.5)j .002
Nights Spent in Psychiatric Hospitals
Baseline (n = 351) 47/178; 118.6 (70.7 to 166.6) 51/173; 95.7 (57.0 to 134.5) 22.9 (−28.8 to 74.6) .38
3 Months (n = 311) 56/156; 342.2 (204.2 to 480.1) 34/155; 194.0 (115.0 to 273.0) 148.2 (11.5 to 284.4) .03
Change at 3 monthsb 223.5 (132.4 to 314.7)l 98.3 (56.2 to 140.3)l 125.3 (36.4 to 214.2)j .01
6 Months (n = 262) 34/133; 254.8 (151.8 to 357.8) 25/129; 318.9 (188.7 to 449.0) −64.1 (−203.5 to 75.3) .37
Change at 6 monthsb 136.1 (79.5 to 192.8)l 223.1 (13.4 to 315.9)l −87.0 (−180.7 to −6.7) .07
12 Months (n = 235) 27/117; 265.9 (157.9 to 373.8) 25/118; 287.8 (169.9 to 405.7) −21.9 (−155.6 to 111.7) .08
Change at 12 monthsb 147.3 (85.3 to 209.2)l 192.1 (111.3 to 272.9)l −44.8 (−131.5 to 41.9) .31
Emergency Department Visitsq
Baseline (n = 351) 87/178; 4.1 (3.3 to 5.0) 85/173; 2.9 (2.4 to 3.4) 1.2 (0.4 to 2.1) .01
3 Months (n = 311) 47/156; 3.3 (2.6 to 4.0) 37/155; 3.2 (2.5 to 4.0) −0.06 (−0.8 to 0.9) .89
Change at 3 monthsb −0.8 (−1.5 to −0.2)f 0.30 (−0.20 to 0.90) −1.2 (−2.0 to −0.3)j .01
6 Months (n = 262) 42/133; 3.8 (2.9 to 4.6) 38/128; 4.4 (3.2 to 5.6) −0.6 (−2.0 to 0.8) .38
Change at 6 monthsb −0.3 (−1.0 to 0.3) 1.5 (0.5 to 2.5)j −1.8 (−3.1 to −0.6)j .004
12 Months (n = 235) 37/117; 5.0 (3.6 to 6.4) 43/118; 3.6 (2.7 to 4.5) 1.4 (−0.1 to 3.0) .07
Change at 12 monthsb 0.9 (−0.1 to 1.9) 0.70 (−0.02 to 1.40) 0.2 (−1.0 to 1.5) .74
Abbreviations: ART, antiretroviral therapy; GLMM, generalized linear mixed
model; LINK LA, Linking Inmates to Care in Los Angeles; SF-12, 12-item
short-form health survey35; ZIP, zero-inflated Poisson.
a Estimated values of each secondary outcome variable using repeated
measures, random-intercept, ZIP models (for count data variables, ie,
the health care services utilization variables), logistic link models (for binary,
0/1 variables), and linear link, normal GLMMs (for continuous variables) with
predictors of intervention arm, categorical time, and intervention × time
interaction term. Themodel accommodates data missing at random, and we
conducted analysis to determine that loss to follow-up was not different
between study arms. The ZIPmodels had 2 uncorrelated random effects,
one for the zero-inflation component and the other for the Poisson
component. All values are estimated at a per 12-month-rate, given at least
1 visit (or hospital night) in the previous 12 months.
bDifference and change values are not always precise totals owing to rounding.
c P value for test between intervention and control arm values at each follow-up
time, and difference-in-difference tested for change from baseline by study
arm, based on a single regressionmodel.
d Probability of reporting currently using (yes/no) at least 1 of a list of all
available ARTmedications (list available at https://aidsinfo.nih.gov/drugs).
e Follow-up interview valueminus baseline value.
f P < .05 for change from baseline.
g Adherence wasmeasured using a visual analogue scale, mean percentage
from0 to 100, where 100 indicates perfect adherence.
h The first parenthetical number in this category reports the number of
nonmissing observations from participants who responded.
i Mean number of knowledge items (yes/no) answered correctly on a 10-item
measure.
j P < .01 for change from baseline.
k SF-12 values are T-scores, normed relative to a USmean (SD) of 50 (10).35
l P < .001 for change from baseline.
mReported as mean number of office visits with physicians for specialty care,
such as ophthalmologist for an eye problem.
n Reported as mean number of visits to get counseling for psychological or
emotional problems.
o Reported as mean number of visits to case managers.
p Reported as mean number of visits to a physician to get prescription
medications to treat drug or alcohol problem.
qReported as mean number of visits to the emergency department.
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12-monthviral suppressionprobability foundinLINKLAissub-
stantially greater than the 24% to 39% levels estimated na-
tionally and the 30% seen among our controls.41,44 In addi-
tion, the decline in viral suppression among controls is
consistentwith thedecline over time in adherence verified by
medication event monitoring systems observed across 14 US
adherence studies.40 The control condition also represents a
fairly robust test of the LINK LA peer navigation intervention
because transitional case management has been effective at
improving linkage tomedical and supportive services after in-
carceration in some studies.45,46
TheLINKLApeer navigation intervention is distinct from
previously published HIV navigation interventions tested in
randomized trials. First, thepeerswerenot “matched” topar-
ticipants basedondemographic characteristics as in somepa-
tientnavigation interventions, but ratherwere selected for ex-
perience relevant to postincarcerated persons. Second,
LINK LA was designed more as a behavior change interven-
tion rather than as another “wraparound” service (eg, case
management), as patient navigation has been described in
some literature.18 Third, we conducted key curriculum ses-
sions during 2 accompaniments to HIV care, conveying im-
portantconcepts incontextandmodelingpatientbehavior.One
review of interventions to enhance retention in HIV care de-
fined accompaniment as a separate kind of intervention from
patient navigation.16 Some navigation interventions con-
sisted of accompaniment to 1 HIV care visit.19,47-50 Fourth,
LINKLA facilitated communicationwith cliniciansduringvis-
its and follow through on their recommendations after-
wards. Fewother navigation interventionshave included this
component,51 but some work points to the critical role of the
patient-clinician relationship in HIV care retention among
postincarceratedpersonsandotherpersons livingwithHIV.51,52
Finally, previous peermentor andpeer support interventions
used non–full-time staff,38 whereas our peer navigators were
staff members paid full-time salaries with benefits, resulting
in little turnover.Perhaps thesedifferenceshelp toexplainwhy
the LINK LA peer navigation intervention was successful, in
contrast to those using other navigation models.
LINK LA peer navigation also improved self-reported re-
tention in HIV primary care, as well as retention and adher-
ence knowledge at 12 months, supporting the viral suppres-
sion outcome finding and suggesting a possible mechanism
consistentwith the conceptualmodel.Moreover, LINKLA im-
proved the use ofmental health care and casemanagement53
in the community, while it reduced emergency department
visits,54 further supporting the main outcome findings.
LINK LA was also particularly effective for those who were
homeless before incarceration. However, it did not signifi-
cantly improve self-reported antiretroviral use or adherence.
More than90%ofparticipants reportedantiretroviral use, and
adherenceexceeded80%atall follow-up timesandbotharms,
suggesting possible overreporting.55 A somewhat similar ran-
domized clinical trial of the effect of patient navigation and
financial incentives onviral suppression amongpeople living
withHIVdischarged fromhospitalsdemonstratedasimilargap
(30%-40% difference) between self-reported adherence and
viral suppression proportions.18
Limitations
There were several limitations to this study. Although viral
load tests were conducted by laboratory assay, baseline mea-
sures were collected by jail staff rather than research staff, so
we lacked control over the test conditions, and results were
often reported only as detectable or undetectable, rather
than number of copies per milliliter. Thus, our outcome
evaluation was limited to assessing only binary viral sup-
pression outcomes rather than change in viral load level.
Since this limitation was not differential by intervention
arm, it should not have biased our key findings, but it
reduced our power to detect smaller changes. Approxi-
mately half of the sample had viral suppression at baseline,
limiting our detection of improvement over time. Attrition
also limited power to detect effects, but fortunately, study
retention was 70% at 12 months; attrition was not differen-
tial by arm; and we replaced a small amount of missing data
on the outcome using public health data. Finally, covariates
and secondary outcomes were self-reported by the partici-
pants. Although the measure we used was previously
validated,56 self-reported antiretroviral medication adher-
ence is often an overestimate.57 In fact, more than 26% of
those with detectable viral load reported 100% adherence, a
level reported by 42% of the overall sample.58-60 Therefore,
it might be expected that we found significant effects on
viral suppression but did not find these effects for self-
reported antiretroviral therapy adherence.
Conclusions
Despite these limitations, this study provides evidence of an
effect of the LINKLApeer navigation intervention sustaining
the level of viral suppression over 12 months, curtailing the
typical decline in viral suppression observed among postin-
carcerated people livingwith HIV.While our datamay gener-
alize to other largemunicipal jails, future research should ex-
amineways to further improveviral suppressionamongpeople
living with HIV after release from incarceration.
ARTICLE INFORMATION
Accepted for Publication: January 5, 2018.
Published Online:March 12, 2018.
doi:10.1001/jamainternmed.2018.0150
Author Affiliations:Department of Medicine,
Division of General Internal Medicine and Health
Services Research, Geffen School of Medicine,
University of California, Los Angeles (Cunningham,
Nakazono, Ettner, Harawa); Department of Health
Policy andManagement, Fielding School of Public
Health, University of California, Los Angeles
(Cunningham, Ettner); Department of Biostatistics,
Fielding School of Public Health, University of
California, Los Angeles (Weiss); Los Angeles County
Sheriff’s, Los Angeles, California (Malek);
Department of Epidemiology, Fielding School of
Public Health, University of California, Los Angeles
(Malek, Harawa); Department of Family Medicine,
Geffen School of Medicine, University of California,
Los Angeles (Shoptaw); Charles R. Drew University
College of Medicine, Los Angeles, California
(Harawa).
Author Contributions:Dr Cunningham had full
access to all the data in the study and takes
responsibility for the integrity of the data and the
accuracy of the data analysis.
Research Original Investigation Peer Navigation Intervention to Engage HIV-Positive Jail Inmates After Release
E10 JAMA Internal Medicine Published onlineMarch 12, 2018 (Reprinted) jamainternalmedicine.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of California - Los Angeles User  on 03/13/2018
Study concept and design: Cunningham,Weiss,
Malek, Shoptaw, Ettner, Harawa.
Acquisition, analysis, or interpretation of data: All
authors.
Drafting of the manuscript: Cunningham,Weiss,
Nakazono, Malek, Shoptaw, Harawa.
Critical revision of the manuscript for important
intellectual content: Cunningham,Weiss, Malek,
Shoptaw, Ettner, Harawa.
Statistical analysis: Cunningham,Weiss, Nakazono,
Malek, Ettner.
Obtained funding: Cunningham, Malek.
Administrative, technical, or material support:
Cunningham, Malek, Harawa.
Study supervision: Cunningham,Weiss, Malek.
Conflict of Interest Disclosures:Dr Shoptaw has
received clinical supplies fromMediciNova Inc for a
different clinical trial. No other disclosures are
reported.
Funding/Support: Primary support for this
research was provided by a grant fromNIH/NIDA,
R01 DA030781 (PI, WE Cunningham). Additional
support for time on this analysis (Weiss, Shoptaw,
Harawa, Cunningham) was provided by the Center
for HIV Identification, Prevention, and Treatment
(CHIPTS) NIMH grant P30-MH58107.
Dr Cunningham’s time was also supported in part
by NIDA R01-DA039934 (MPIs, Schneider, Harawa,
Kayo); NIMH R01-MH103076 (PI, Cunningham);
NIA P30-AG021684 (RCMAR/CHIME; PI Mangione);
NIMHD R01-MD011773 (PI, Cunningham); NINR
Grants: R01-NR017334 (PI, Bogart), and
R01-NR4014789 (PI, Ford); and the UCLA Clinical
and Translational Science Institute (CTSI) NIH/
NCATS grants UL1-TR001881 (PI, Dubinett) and
TL1-TR001883 (PI, Ettner).
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Disclaimer: The content is solely the responsibility
of the authors and does not necessarily represent
the views of the NIH.
Additional Contributions.We thank the following
individuals for their contributions to the study:
Jimmy Ngo, BA; Danielle Seiden, MPP; Jenna
Arzinger, MPH; Darlene Hernandez; Garret Cox,
MPH; Martha Tadesse, RN; Diana Perez, RN; Joanne
Oliver; Maria Meligitone; Al Brown; Richard
Hamilton; themany leaders and staff of the Division
of HIV and STD Programs, LA County Department
of Public Health, the LA County Sheriff’s
Department, and the study participants living with
HIV. They received no compensation for their
contributions beyond that received in the normal
course of their employment or that reported in this
article.
REFERENCES
1. Giordano TP, Suarez-Almazor ME, Grimes RM.
The population effectiveness of highly active
antiretroviral therapy: are good drugs good
enough? Curr HIV/AIDS Rep. 2005;2(4):177-183.
2. Gardner EM, McLees MP, Steiner JF, Del Rio C,
BurmanWJ. The spectrum of engagement in HIV
care and its relevance to test-and-treat strategies
for prevention of HIV infection. Clin Infect Dis. 2011;
52(6):793-800.
3. Tobias C, CunninghamWE, Cunningham CO,
PoundsMB. Making the connection: the
importance of engagement and retention in HIV
medical care. AIDS Patient Care STDS. 2007;21(suppl
1):S3-S8.
4. Spaulding AC, Seals RM, PageMJ, Brzozowski
AK, RhodesW, Hammett TM. HIV/AIDS among
inmates of and releasees fromUS correctional
facilities, 2006: declining share of epidemic but
persistent public health opportunity. PLoS One.
2009;4(11):e7558.
5. Sabin KM, Frey RL Jr, Horsley R, Greby SM.
Characteristics and trends of newly identified HIV
infections among incarcerated populations: CDC
HIV voluntary counseling, testing, and referral
system, 1992-1998. J Urban Health. 2001;78(2):
241-255.
6. Maruschak LM. U.S. Department of Justice,
Office of Justice Programs; Bureau of Justice
Statistics. HIV in Prisons, 2006. April 22, 2008.
https://www.bjs.gov/content/pub/pdf/hivp06.pdf.
Accessed January 16, 2018.
7. Harawa NT, Amani B, Bowers JR, Sayles JN,
CunninghamWE. Understanding interactions of
formerly incarcerated HIV-positive men and
transgender womenwith substance use treatment,
medical, and criminal justice systems. Int J Drug
Policy. 2017;Oct(48):63-71.
8. Draine J, Ahuja D, Altice FL, et al. Strategies to
enhance linkages between care for HIV/AIDS in jail
and community settings. AIDS Care. 2011;23(3):
366-377.
9. Springer SA, Pesanti E, Hodges J, Macura T,
Doros G, Altice FL. Effectiveness of antiretroviral
therapy among HIV-infected prisoners:
reincarceration and the lack of sustained benefit
after release to the community. Clin Infect Dis.
2004;38(12):1754-1760.
10. Meyer JP, Cepeda J, Wu J, Trestman RL, Altice
FL, Springer SA. Optimization of human
immunodeficiency virus treatment during
incarceration: viral suppression at the prison gate.
JAMA Intern Med. 2014;174(5):721-729.
11. Rapp RC, Ciomcia R, Zaller N, Draine J, Ferguson
A, Cagey R. The role of jails in engaging PLWHA in
care: from jail to community. AIDS Behav. 2013;17
(suppl 2):S89-S99.
12. Palepu A, Tyndall MW, Chan K, Wood E,
Montaner JS, Hogg RS. Initiating highly active
antiretroviral therapy and continuity of HIV care:
the impact of incarceration and prison release on
adherence andHIV treatment outcomes.Antivir Ther.
2004;9(5):713-719.
13. Baillargeon J, Giordano TP, Rich JD, et al.
Accessing antiretroviral therapy following release
from prison. JAMA. 2009;301(8):848-857.
14. Wohl DA, Golin CE, Knight K, et al. Randomized
controlled trial of an intervention tomaintain
suppression of HIV viremia after prison release: the
imPACT trial. J Acquir Immune Defic Syndr. 2017;75
(1):81-90.
15. Bradford JB, Coleman S, CunninghamW. HIV
system navigation: an emergingmodel to improve
HIV care access. AIDS Patient Care STDS. 2007;21
(suppl 1):S49-S58.
16. Higa DH, Marks G, Crepaz N, Liau A, Lyles CM.
Interventions to improve retention in HIV primary
care: a systematic review of U.S. studies. Curr
HIV/AIDS Rep. 2012;9(4):313-325.
17. Fowler T, Steakley C, Garcia AR, Kwok J, Bennett
LM. Reducing disparities in the burden of cancer:
the role of patient navigators. PLoS Med. 2006;3
(7):e193.
18. Metsch LR, Feaster DJ, Gooden L, et al. Effect of
patient navigation with or without financial
incentives on viral suppression among hospitalized
patients with HIV infection and substance use:
a randomized clinical trial. JAMA. 2016;316(2):
156-170.
19. Okeke NL, Ostermann J, Thielman NM.
Enhancing linkage and retention in HIV care:
a review of interventions for highly resourced and
resource-poor settings. Curr HIV/AIDS Rep. 2014;11
(4):376-392.
20. Tobias CR, Rajabiun S, Franks J, et al. Peer
knowledge and roles in supporting access to care
and treatment. J Community Health. 2010;35(6):
609-617.
21. Kulkarni SP. The LAC HIV epidemic and TLC+
response presentation to LAC Board of Supervisors.
Los Angeles County Department of Public Health
Division of HIV and STD Programs; June 5, 2012.
http://publichealth.lacounty.gov/dhsp/Reports/HIV
/TLCBrief4-12.pdf. Accessed January 16, 2018.
22. Malek M, Bazazi AR, Cox G, et al. Implementing
opt-out programs at Los Angeles county jail:
a gateway to novel research and interventions.
J Correct Health Care. 2011;17(1):69-76.
23. Panel on Antiretroviral Guidelines for Adults
and Adolescents. Guidelines for the Use of
Antiretroviral Agents in HIV-1-Infected Adults and
Adolescents. Washington, DC: Department of Health
and Human Services; 2011.
24. Gifford AL, Sengupta S. Self-management
health education for chronic HIV infection.AIDS Care.
1999;11(1):115-130.
25. Bandura A. Self-efficacy: The Exercise of Control.
New York, NY: W.H. Freeman; 1997.
26. Huynh AK, Kinsler JJ, CunninghamWE, Sayles
JN. The role of mental health in mediating the
relationship between social support and optimal
ART adherence. AIDS Care. 2013;25(9):1179-1184.
27. Kinsler JJ, WongMD, Sayles JN, Davis C,
CunninghamWE. The effect of perceived stigma
from a health care provider on access to care
among a low-income HIV-positive population. AIDS
Patient Care STDS. 2007;21(8):584-592.
28. Sayles JN, WongMD, Kinsler JJ, Martins D,
CunninghamWE. The association of stigma with
self-reported access to medical care and
antiretroviral therapy adherence in persons living
with HIV/AIDS. J Gen Intern Med. 2009;24(10):
1101-1108.
29. Schuster MA, Collins R, CunninghamWE, et al.
Perceived discrimination in clinical care in a
nationally representative sample of HIV-infected
adults receiving health care. J Gen Intern Med.
2005;20(9):807-813.
30. Andersen R, Bozzette S, Shapiro M, et al.
Access of vulnerable groups to antiretroviral
therapy among persons in care for HIV disease in
the United States: HCSUS Consortium: HIV cost and
services utilization study.Health Serv Res. 2000;35
(2):389-416.
31. CunninghamWE, Hays RD,Williams KW, et al.
Access to medical care and health-related quality of
Peer Navigation Intervention to Engage HIV-Positive Jail Inmates After Release Original Investigation Research
jamainternalmedicine.com (Reprinted) JAMA Internal Medicine Published onlineMarch 12, 2018 E11
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of California - Los Angeles User  on 03/13/2018
life for low-income persons with symptomatic
human immunodeficiency virus.Med Care. 1995;33
(7):739-754.
32. CunninghamWE, Andersen RM, Katz MH, et al.
The impact of competing subsistence needs and
barriers on access to medical care for persons with
human immunodeficiency virus receiving care in
the United States.Med Care. 1999;37(12):1270-1281.
33. CasewatchMillennium [computer program].
Los Angeles, California: Automated Case
Management Systems, Inc; 1987.
34. Midanik LT, Hines AM, Barrett DC, Paul JP,
Crosby GM, Stall RD. Self-reports of alcohol use,
drug use and sexual behavior: expanding the
timeline follow-back technique. J Stud Alcohol.
1998;59(6):681-689.
35. Ware J Jr, Kosinski M, Keller SDA. A 12-item
short-form health survey: construction of scales
and preliminary tests of reliability and validity.Med
Care. 1996;34(3):220-233.
36. Weiss RE.Modeling Longitudinal Data. NewYork,
NY: Springer; 2005.
37. Ning Li, Elashoff DA, RobbinsWA, Lin Xun.
A hierarchical zero-inflated log-normal model for
skewed responses. Stat Methods Med Res. 2011;20
(3):175-189.
38. Giordano TP, Cully J, Amico KR, et al.
A randomized trial to test a peer mentor
intervention to improve outcomes in persons
hospitalized with HIV infection. Clin Infect Dis.
2016;63(5):678-686.
39. Stitzer M, Matheson T, Cunningham C, et al.
Enhancing patient navigation to improve
intervention session attendance and viral load
suppression of persons with HIV and substance
use: a secondary post hoc analysis of the Project
HOPE study. Addict Sci Clin Pract. 2017;12(1):16.
40. Wilson IB, Bangsberg DR, Shen J, et al;
Multisite Adherence Collaboration on HIV 14
Investigators. Heterogeneity among studies in rates
of decline of antiretroviral therapy adherence over
time: results from themultisite adherence
collaboration on HIV 14 study. J Acquir Immune
Defic Syndr. 2013;64(5):448-454.
41. Iroh PA, Mayo H, Nijhawan AE. The HIV care
cascade before, during, and after incarceration:
a systematic review and data synthesis. Am J Public
Health. 2015;105(7):e5-e16.
42. Springer SA, Friedland GH, Doros G, Pesanti E,
Altice FL. Antiretroviral treatment regimen
outcomes among HIV-infected prisoners.HIV Clin
Trials. 2007;8(4):205-212.
43. CohenMS, Chen YQ, McCauley M, et al; HPTN
052 Study Team. Prevention of HIV-1 infection with
early antiretroviral therapy.N Engl J Med. 2011;365
(6):493-505.
44. Hall HI, Holtgrave DR, Maulsby C. HIV
transmission rates from persons living with HIV
who are aware and unaware of their infection. AIDS.
2012;26(7):893-896.
45. Coviello DM, Zanis DA, Wesnoski SA, Alterman
AI. The effectiveness of outreach case management
in re-enrolling dischargedmethadone patients.
Drug Alcohol Depend. 2006;85(1):56-65.
46. Sorensen JL, Masson CL, Delucchi K, et al.
Randomized trial of drug abuse treatment-linkage
strategies. J Consult Clin Psychol. 2005;73(6):
1026-1035.
47. Rajabiun S, Mallinson RK, McCoy K, et al.
“Getting me back on track”: the role of outreach
interventions in engaging and retaining people
living with HIV/AIDS in medical care. AIDS Patient
Care STDS. 2007;21(S1)(suppl 1):S20-S29.
48. Liau A, Crepaz N, Lyles CM, et al; HIV/AIDS
Prevention Research Synthesis (PRS) Team.
Interventions to promote linkage to and utilization
of HIVmedical care among HIV-diagnosed persons:
a qualitative systematic review, 1996-2011. AIDS
Behav. 2013;17(6):1941-1962.
49. Gardner LI, Metsch LR, Anderson-Mahoney P,
et al; Antiretroviral Treatment and Access Study
Group. Efficacy of a brief case management
intervention to link recently diagnosed HIV-infected
persons to care. AIDS. 2005;19(4):423-431.
50. Molitor F, Waltermeyer J, MendozaM, et al.
Locating and linking to medical care HIV-positive
persons without a history of care: findings from the
California Bridge Project. AIDS Care. 2006;18(5):
456-459.
51. Gardner LI, Giordano TP, Marks G, et al;
Retention in Care Study Group. Enhanced personal
contact with HIV patients improves retention in
primary care: a randomized trial in 6 US HIV clinics.
Clin Infect Dis. 2014;59(5):725-734.
52. Bracken N, Hilliard C, McCuller WJ, Harawa NT.
Facilitators of HIVmedical care engagement among
former prisoners. AIDS Educ Prev. 2015;27(6):
566-583.
53. Katz MH, CunninghamWE, Fleishman JA, et al.
Effect of case management on unmet needs and
utilization of medical care andmedications among
HIV-infected persons. Ann Intern Med. 2001;135(8,
pt 1):557-565.
54. CunninghamWE, Sohler NL, Tobias C, et al.
Health services utilization for people with HIV
infection: comparison of a population targeted for
outreach with the U.S. population in care.Med Care.
2006;44(11):1038-1047.
55. Simoni JM, Huh D,Wang Y, et al. The validity of
self-reportedmedication adherence as an outcome
in clinical trials of adherence-promotion
interventions: findings from theMACH14 study.
AIDS Behav. 2014;18(12):2285-2290.
56. Giordano TP, Guzman D, Clark R, Charlebois ED,
Bangsberg DR. Measuring adherence to
antiretroviral therapy in a diverse population using
a visual analogue scale. HIV Clin Trials. 2004;5(2):
74-79.
57. Wagner GJ, Rabkin JG. Measuring medication
adherence: are missed doses reportedmore
accurately then perfect adherence? AIDS Care.
2000;12(4):405-408.
58. Bangsberg DR. Less than 95% adherence to
nonnucleoside reverse-transcriptase inhibitor
therapy can lead to viral suppression. Clin Infect Dis.
2006;43(7):939-941.
59. Kobin AB, Sheth NU. Levels of adherence
required for virologic suppression among newer
antiretroviral medications. Ann Pharmacother. 2011;
45(3):372-379.
60. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA,
Zingman BS. HIV-infected patients receiving
lopinavir/ritonavir-based antiretroviral therapy
achieve high rates of virologic suppression despite
adherence rates less than 95%. J Acquir Immune
Defic Syndr. 2007;45(1):4-8.
Research Original Investigation Peer Navigation Intervention to Engage HIV-Positive Jail Inmates After Release
E12 JAMA Internal Medicine Published onlineMarch 12, 2018 (Reprinted) jamainternalmedicine.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of California - Los Angeles User  on 03/13/2018
